Fig. 4

Cantharidin inhibits PI3K/AKT/mTOR signaling pathway. A Protein expression of PI3K-110α, PI3K-110β, PI3K-110γ, p-PI3K-P85/55 and PI3K-P85 in MDA-MB-231 cells at indicated treatment. B Protein expression of PI3K-110α, PI3K-110β, PI3K-110γ, p-PI3K-P85/55 and PI3K-P85 in MDA-MB-468 cells at indicated treatment. C Protein expression of p-AKT, AKT, p-mTOR and mTOR in MDA-MB-231 cells at indicated treatment. D Protein expression of p-AKT, AKT, p-mTOR and mTOR in MDA-MB-468 cells at indicated treatment. E Protein expression of p-AKT, AKT, p-mTOR and mTOR in MDA-MB-231 cells. The cells were treated with cantharidin or pretreated with EGFR inhibitor AG1478 for 24 h. F Protein expression of p-AKT, AKT, p-mTOR and mTOR in MDA-MB-468 cells. The cells were treated with cantharidin or pretreated with EGFR inhibitor AG1478 for 24 h. G Protein expression of p-AKT, AKT, p-mTOR and mTOR in MDA-MB-231 cells. The cells were treated with cantharidin or pretreated with EGF for 10 min. H Protein expression of p-AKT, AKT, p-mTOR and mTOR in MDA-MB-468 cells. The cells were treated with cantharidin or pretreated with EGF for 30 min